Is the Mounjaro injection safe for weight loss?

What does the clinical trial record show about Mounjaro's safety?

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and followed them for 72 weeks. Alongside the weight-loss results (average reductions of around 20–21% of body weight at the 15 mg dose in clinical trials) the researchers also tracked adverse events systematically. The most commonly reported problems were gastrointestinal: nausea, diarrhoea, vomiting, and constipation. These were mostly mild to moderate in severity and occurred most frequently after starting treatment or after a dose increase, typically settling as the body adjusted. Fatigue, headache, and injection-site reactions were also reported but less common.

NICE reviewed this evidence in detail before recommending tirzepatide for NHS use (TA1026, published December 2024). The committee assessed the benefit-risk balance as favourable for adults meeting the eligibility criteria, a finding grounded in the full safety dataset, not just the headline weight-loss numbers. For a fuller look at how the clinical case for Mounjaro was built, the evidence on Mounjaro for weight loss covers the trial programme in more detail.

Mounjaro's Black Triangle designation means every suspected side effect is reported to the MHRA and reviewed on an ongoing basis. That process doesn't stop at licensing, it continues for as long as the medicine is on the market, which is why the safety picture is continuously updated.

Which side effects should you genuinely watch for?

Most people starting the Mounjaro injection notice some digestive disruption in the first few weeks. That is expected and, for the majority, manageable. Eating smaller portions, avoiding very fatty meals, and staying well-hydrated during a dose increase all make a practical difference, small adjustments that take under a minute to plan before each meal.

The side effects that warrant more attention are less common but important to recognise. In January 2026, the MHRA published a Drug Safety Update on GLP-1 medicines and acute pancreatitis: severe, persistent stomach pain that radiates towards the back, with or without vomiting, is a signal to stop the injection and seek urgent medical help. It is uncommon, but the MHRA flagged it because it can be serious if missed. Gallbladder problems (pain in the upper right abdomen, particularly after eating) are another side effect to know. Dehydration from prolonged vomiting or diarrhoea can, in rare cases, put pressure on the kidneys, so persistent GI illness isn't something to push through without medical input.

Allergic reactions are rare but possible. Swelling of the face or throat, difficulty breathing, or a rapid heartbeat after injecting means calling 999. You can report any suspected side effect through the MHRA Yellow Card scheme, that reporting is how the safety database stays current, and patients can submit reports directly, not just clinicians.

When should you get medical help urgently?

The NHS patient information for tirzepatide sets out the full list of warning signs clearly. The ones that cannot wait for a routine prescriber check:

Severe stomach pain spreading to the back, possible pancreatitis, stop the injection and go to A&E or call 111 immediately. Signs of a serious allergic reaction: swelling around the face, lips or throat, a rash, or breathing difficulty. Symptoms of severe dehydration after prolonged vomiting or diarrhoea: dizziness, very dark urine, not passing urine. Any thoughts of self-harm or sudden low mood, these are listed as possible adverse effects and your GP or 111 should be contacted the same day.

For anything that is uncomfortable but not urgent (persistent nausea at a new dose, mild constipation, a tender injection site) your prescriber is the right first call rather than stopping treatment without guidance. If you have a question that cannot wait, our aftercare team is available seven days a week.

Who should not use the Mounjaro injection for weight loss?

Licensing and clinical safety data define clear groups for whom Mounjaro is not suitable. The injection is not licensed for people under 18. It is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive, the MHRA advises effective contraception during treatment and a wash-out period before attempting conception. For people using oral contraceptives specifically, an additional non-oral method is needed for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying may reduce pill absorption.

A personal or family history of medullary thyroid carcinoma, or the hereditary condition MEN2 (multiple endocrine neoplasia type 2), rules out Mounjaro. A history of pancreatitis requires careful prescriber discussion before any GLP-1 medicine. Certain gastrointestinal conditions also need individual assessment.

None of this is a checklist to run through yourself. The Mounjaro overview covers the licensed indication in full, and our prescribers go through your full medical history as part of the consultation, that assessment is where questions about your specific situation belong. If you are weighing up whether the Mounjaro injection is used for weight loss in a way that suits your circumstances, further detail on Mounjaro's safety considerations may help you prepare for that conversation, and our page on how Mounjaro weight loss injections work in practice can also be a useful starting point.